Crestone, Inc. is a drug discovery and development company focused on developing novel treatments
for serious bacterial infections. The company currently has two
programs that address areas of significant and growing unmet medical
need, both with novel mechanism of action agents.
antibiotic for Clostridium difficile infections. CRS3123 (formerly known as REP3123) is in development
for the treatment of C. difficile infection (CDI). This disease occurs when toxin-producing
bacteria colonize the gastrointestinal tract, and is associated with significant morbidity and mortality. Due to the development of hyper-virulent drug-resistant strains, incidence has more than doubled in the last decade. Preclinical testing of CRS3123
shows superior performance over existing therapies, which have significant shortcomings. Phase 1 clinical studies for CRS3123
are currently being conducted with the NIAID Division of Microbiology and Infectious Disease (DMID).
oral agents for Gram-positive infections. Crestone is optimizing a novel class of DNA replication inhibitors with Gram-positive antibacterial activity. This promising
chemical series is currently in advanced lead optimization,
funded by an SBIR grant from NIAID and by a Bioscience Discovery Evaluation Grant from the State of Colorado. These molecules
selectively inhibit an essential component of the replicative DNA polymerase
complex and are potent, orally available, and effective against all clinically-relevant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA),
enterococci (VRE), penicillin-resistant Streptococcus pneumoniae (PRSP) and Bacillus anthracis. We anticipate development of a drug
similar to Zyvox in spectrum, but with key advantages such as bactericidal activity and improved safety.